Janssen Touts Positive Data For Tremfya, Stelara
Janssen Touts Positive Data For Tremfya, Stelara Published: May 25, 2022 By Vanessa Doctor, RN BioSpace Janssen Pharmaceutical shared positive
Janssen Touts Positive Data For Tremfya, Stelara Published: May 25, 2022 By Vanessa Doctor, RN BioSpace Janssen Pharmaceutical shared positive
Researchers may have unlocked mechanism driving inflammation in rheumatoid arthritis Published: May 18, 2022 By Jazmine
Recently, ZUS Coffee made headlines after a customer had purchased a cake from their Palm Mall outlet in Seremban, which appeared to have mould in
U.S. FDA extends review period for expanded use of AbbVie’s psoriasis drug February 28, 2022; 4:53 PM EST (Reuters) – AbbVie Inc (ABBV.N) said on
I have Crohn’s disease. I was diagnosed in February of 2021, so I am coming up on a year of clarity about my health. Prior to my official
AbbVie Leans on Skyrizi, Rinvoq as Humira Rides off the Patent Cliff Published: Feb 02, 2022 By Mark Terry BioSpace AbbVie reported its
As a clinical health psychologist, I have the privilege of working with patients who live with Inflammatory Bowel Disease (IBD). In the past I’ve
There’s a fungus among us. Or more like within us. While that might make you cringe at first glance, the truth is, these microscopic fungi might
By exploring mutations involved in inflammatory bowel disease (IBD), researchers have provided insights into the crosstalk between genetics and
“You’re honestly doing a really good job. I know all you see is all the ways you think you’re failing. But I promise, you’re doing OK, and no
An international team of scientists has identified a new connection between certain molecules produced by the microbiome and the function of a
This post contains affiliate links. Click here to see what that means!In order to support our blogging activities, we may receive monetary
It’s safe to say just about everyone experiences tummy upset and digestive problems from time to time. But if you’re having persistent pain,
The close connection between specific gut microbes and inflammation has been of longstanding interest in inflammatory bowel diseases (IBDs). Although
Eli Lilly has walked away from a major indication for its blockbuster hopeful mirikizumab, shelving plans to file it for psoriasis as the market is